Skip to Main Content

dementia

Dementia is the broad term for a decline in cognitive function that affects memory, thinking, and behavior. Alzheimer’s disease is a form of dementia, and stories here track the latest dementia research and dementia treatments.

Articles include a look at the new Alzheimer’s drug Leqembi, the link between air pollution and dementia risk, and a new field of Alzheimer’s research involving CRISPR technologies.

Latest

Health Rachel Cohrs

STAT Plus: Medicare to cover more brain scans related to Alzheimer’s drugs

Health Felice J. Freyer — Boston Globe

STAT Plus: A fraught question for the children of Alzheimer’s: Is it coming for us?

Health Nicholas St. Fleur

How Seth Rogen and Lauren Miller Rogen are using comedy to support Alzheimer’s care

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Drug firms test medicines to halt Alzheimer’s before symptoms appear

Biotech Robert Weisman — Boston Globe

STAT Plus: Workforce, capacity constraints slow ramp-up of new Alzheimer’s drug Leqembi

Biotech Allison DeAngelis

STAT Plus: Neuroscience startup Neumora files for IPO

Health Abdullahi Tsanni

Long-term exposure to particulates from wildfire smoke linked to dementia risk, new study finds

Health Bree Iskandar

How a beautiful symptom of a brutal dementia informs our understanding of creativity

All Coverage

Politics John Wilkerson

STAT Plus: Medicare wants to improve Alzheimer’s care, but sidesteps drug prices

Health Tech Brittany Trang

STAT Plus: As Alzheimer’s drugs hit the market, the race for early detection blood tests heats up

advertisement

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

Biotech Rachel Cohrs

STAT Plus: Medicare to cover more brain scans for Alzheimer’s patients

Biotech Adam Feuerstein

STAT Plus: Detailed data confirm benefits — and risks — of Eli Lilly’s Alzheimer’s drug

In the Lab Andrew Joseph

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer’s

Biotech Andrew Joseph

STAT Plus: With momentum on Alzheimer’s therapies, Europe sees delivery challenges ahead, too

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

Health Rachel Cohrs

STAT Plus: How are insurers handling the Alzheimer’s drug Leqembi and related scans?

Biotech Brittany Trang

STAT Plus: Eisai executive who helped lead development of Alzheimer’s drug to retire

First Opinion Howard M. Fillit

We finally have new Alzheimer’s drugs. How do we decide who gets them?

First Opinion Podcast Torie Bosch

Listen: Is the medical system ready for Alzheimer’s drugs that work?

First Opinion Jason Karlawish

The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages

Biotech Adam Feuerstein and Damian Garde

STAT Plus: FDA panel unanimously endorses Eisai’s Alzheimer’s drug

Biotech Adam Feuerstein and Damian Garde

STAT Plus: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Politics Rachel Cohrs

STAT Plus: Democrats blast Biden administration over Alzheimer’s drug plans

Politics Rachel Cohrs

STAT Plus: Medicare holds firm on Alzheimer’s drug coverage policy

Politics Kerry Dooley Young

STAT Plus: Will Medicare cover it? Drugs like Aduhelm are challenging its standard

D.C. Diagnosis Sarah Owermohle

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on